Latest News

Jun 11, 2019
ReViral Appoints Alex C. Sapir as Chief Executive Officer
  • Proven leader with extensive corporate strategy experience in the biotechnology sector
  • Dr. Eddy Littler to remain as Chief Operating Officer
May 14, 2019
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)

Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research (ICAR)

London, UK,...

Apr 8, 2019
ReViral Announces Grant of Key US Composition of Matter Patent For Their Respiratory Syncytial Virus inhibitor programme

• Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
• The counterpart to this patent has been issued in...

Apr 5, 2019
ReViral to present at Microbiology Society Annual Conference 2019

ReViral's Chief Scientific Officer, Stuart Cockerill, will be giving an oral presentation at the Microbiology Society Annual Conference 2019 (8th-11th April) in Belfast. The presentation entitled "Design,...

Feb 26, 2019
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials

London, UK, 26th February 2019: ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced the...

Archived News
Nov 14, 2018
ReViral Announces Publication of Article in Journal of Medicinal Chemistry 'Perspectives'
Aug 1, 2018
ReViral announces Series B investment
Feb 5, 2018
Positive results achieved in ReViral’s Phase IIa RSV challenge study
Sep 5, 2017
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus
Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
Sep 8, 2015
ReViral announces US$21 million fundraising to advance clinical development of a novel anti-viral drug
Upcoming Events
20th SCI/RSC Medicinal Chemistry Symposium
Sep 8, 2019 to Sep 11, 2019
Cambridge, UK
More Information
IDWeek 2019
Oct 2, 2019 to Oct 6, 2019
Washington DC, USA
More Information
Nov 11, 2019 to Nov 13, 2019
Hamburg, Germany
More Information
RSVVW'19 5th ReSViNET Conference
Nov 12, 2019 to Nov 14, 2019
Accra, Ghana
More Information
Biotech Showcase
Jan 13, 2020 to Jan 15, 2020
San Francisco
More Information
Past Events
J.P. Morgan 37th Annual Healthcare Conference
Jan 7, 2019 to Jan 10, 2019
San Francisco
More Information
Microbiology Society Annual Conference 2019
Apr 8, 2019 to Apr 11, 2019
Belfast, UK
More Information
32nd International Conference on Antiviral Research (ICAR)
May 12, 2019 to May 15, 2019
Baltimore, USA
More Information
BIO 2019
Jun 3, 2019 to Jun 6, 2019
Philadelphia, PA
More Information
Jefferies Healthcare Conference
Jun 4, 2019 to Jun 7, 2019
New York
More Information